Skip to content

Basal Bolus vs. Sliding Scale for Treatment of Diabetic Patients in Medical Wards

A Randomized, Comparative Study of Basal-bolus Insulin Versus Conventional Sliding-scale Regular Insulin Therapy in Management of Non-critically Ill Patients Hospitalized in the Medical Ward.

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01594060
Enrollment
36
Registered
2012-05-08
Start date
2012-06-30
Completion date
2014-10-31
Last updated
2018-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus Type 2

Brief summary

A comparison of two treatment approaches for hyperglycemia in diabetic patients hospitalized in the medical department. The first approach is called basal-bolus in which 4 insulin shots are given daily ( 3 short acting before meals and one long acting before bed time). The second approach is called sliding scale in which short acting insulin alone is given before meals and before bed time according to the patient's glucose values. The aim is to keep fasting glucose between 140-180 mg/dl.

Interventions

DRUGInsulin, regular - act rapid

4 shots of regular insulin: 3 before meals and one at bedtime.

DRUGInsulin glulisine, Insulin glargine

1 shot glargine at bedtime 3 shots glulisine before meals

Sponsors

HaEmek Medical Center, Israel
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 100 Years
Healthy volunteers
No

Inclusion criteria

* Patients admitted to internal medicine ward with blood glucose (BG) between 140-400 mg/dl. * Known history (\>6months) of diabetes. * Aged 18-80 years old. * Previous therapy including either diet alone or any combination of oral hypoglycemia agents, glucagon-like peptide 1 (GLP-1) analogs and long acting insulin analogs or Neutral Protamine Hagedorn (NPH).

Exclusion criteria

* Pregnancy * Patients with ketoacidosis * Patients with unknown history of diabetes * Patients with type 1 diabetes mellitus * Patients with clinically relevant hepatic disease or renal impairment ( serum creatinine≥2.5 mg/dl) * Use of corticosteroid therapy * Patient with any mental disorder preventing him to cooperate and give informed consent. * Patients on multiple daily doses of insulin regimen.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026